Abstract:Introduction: Structure-based drug design is a wide area of identification of selective inhibitors of a target of interest. From the time of the availability of three dimensional structure of the drug targets, mostly the proteins, many computational methods had emerged to address the challenges associated with drug design process. Particularly, drug-likeness, druggability of the target protein, specificity, off-target binding, etc., are the important factors to determine the efficacy of new chemical inhibitors. Objective: The aim of the present research was to improve the drug design strategies in field of design of novel inhibitors with respect to specific target protein in disease pathology. Recent statistical machine learning methods applied for structural and chemical data analysis had been elaborated in current drug design field. Methods: As the size of the biological data shows a continuous growth, new computational algorithms and analytical methods are being developed with different objectives. It covers a wide area, from protein structure prediction to drug toxicity prediction. Moreover, the computational methods are available to analyze the structural data of varying types and sizes of which, most of the semi-empirical force field and quantum mechanics based molecular modeling methods showed a proven accuracy towards analysing small structural data sets while statistics based methods such as machine learning, QSAR and other specific data analytics methods are robust for large scale data analysis. Results: In this present study, the background has been reviewed for new drug lead development with respect specific drug targets of interest. Overall approach of both the extreme methods were also used to demonstrate with the plausible outcome. Conclusion: In this chapter, we focus on the recent developments in the structure-based drug design using advanced molecular modeling techniques in conjunction with machine learning and other data analytics methods. Natural products based drug discovery is also discussed.

Structure-Based Drug Design Strategies and Challenges

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Structure-based drug design: aiming for a perfect fit

Towards Structure-Based Protein Drug Design

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Computational Methods for Structure-Based Drug Design Through System Biology.

Structure-based Drug Design Benchmark: Do 3D Methods Really Dominate?

Structure-Based Approach For In-Silico Drug Designing

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

Drug Design based on Protein Structure Network

A Systematic Survey in Geometric Deep Learning for Structure-based Drug Design

Recent Trends in Drug Design and Discovery

Protein Structure Network-based Drug Design

Systems Biology Brings New Dimensions for Structure-Based Drug Design

Sequence-based drug design as a concept in computational drug design

Computational approaches streamlining drug discovery

Combined strategies in structure-based virtual screening

Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances

Recent Advances in Automated Structure-Based De Novo Drug Design